文献速递肝病

激活单磷酸腺苷活化蛋白激酶介导成纤维细胞生长因子1对小鼠非酒精性脂肪性肝病的保护作用

Activating Adenosine Monophosphate-Activated Protein Kinase Mediates Fibroblast Growth Factor 1 Protection From Nonalcoholic Fatty Liver Disease in Mice.
PubMed 文献 · Hepatology · 2021-01-01

研究探讨携带3个肝素结合位点替换的非促有丝分裂FGF1变体(FGF1△HBS)对非酒精性脂肪性肝病(NAFLD)的治疗活性及机制。在9月龄 leptin 受体基因纯合突变糖尿病(db/db)NAFLD小鼠中,FGF1△HBS 给药有效,肝脏重量、脂质沉积和炎症下降,肝损伤减轻。机制上 FGF1△HBS 通过肝细胞 FGFR4 激活 AMPK 发挥作用。

要点

  • FGF1△HBS 在 db/db 糖尿病 NAFLD 小鼠中减轻肝脏重量、脂质沉积、炎症和肝损伤。
  • FGF1△HBS 通过肝细胞 FGFR4 激活 AMPK,介导抗氧化和改善脂质代谢。
  • 肝特异性 AMPK 敲除取消 FGF1△HBS 对高脂/高蔗糖饮食诱导的肝脏脂肪变性的治疗作用。

核心结论

  • FGF1△HBS 可有效预防和逆转肝脏脂肪变性及脂肪性肝炎,其作用通过肝细胞 FGFR4 激活 AMPK 实现。

研究设计与样本

  • 研究在9月龄携带瘦素受体基因纯合突变的糖尿病(db/db)NAFLD小鼠中给予 FGF1△HBS,并在棕榈酸处理的肝细胞中进行机制研究,以及在高脂/高蔗糖饮食诱导的肝脂肪变性小鼠中行肝特异性 AMPK 敲除实验。
  • 此外在载脂蛋白E敲除小鼠中评估 FGF1△HBS 对高脂/高胆固醇饮食诱导的脂肪性肝炎和纤维化的作用。

主要发现

  • 在9月龄 db/db NAFLD 小鼠中,FGF1△HBS 给药后肝脏重量、脂质沉积和炎症下降,肝损伤减轻。
  • FGF1△HBS 通过促进核因子E2相关因子2(Nrf2)核转位和抗氧化蛋白表达升高来减少氧化应激。
  • FGF1△HBS 抑制脂质生成基因的活性和/或表达,伴随 AMPK 及其底物磷酸化。
  • 在棕榈酸处理的肝细胞中,siRNA 敲低 Nrf2 仅取消 FGF1△HBS 的抗氧化作用,但不改善脂质代谢;药物或 siRNA 抑制 AMPK 则取消 FGF1△HBS 对氧化应激和脂质代谢的益处,且该益处依赖 FGFR4。
  • 肝特异性 AMPK 敲除取消 FGF1△HBS 对高脂/高蔗糖饮食诱导的肝脏脂肪变性的治疗作用;FGF1△HBS 改善载脂蛋白E敲除小鼠高脂/高胆固醇饮食诱导的脂肪性肝炎和纤维化。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Fibroblast growth factor (FGF) 1 demonstrated protection against nonalcoholic fatty liver disease (NAFLD) in type 2 diabetic and obese mice by an uncertain mechanism. This study investigated the therapeutic activity and mechanism of a nonmitogenic FGF1 variant carrying 3 substitutions of heparin-binding sites (FGF1△HBS ) against NAFLD. APPROACH AND RESULTS: FGF1△HBS administration was effective in 9-month-old diabetic mice carrying a homozygous mutation in the leptin receptor gene (db/db) with NAFLD; liver weight, lipid deposition, and inflammation declined and liver injury decreased. FGF1△HBS reduced oxidative stress by stimulating nuclear translocation of nuclear erythroid 2 p45-related factor 2 (Nrf2) and elevation of antioxidant protein expression. FGF1△HBS also inhibited activity and/or expression of lipogenic genes, coincident with phosphorylation of adenosine monophosphate-activated protein kinase (AMPK) and its substrates. Mechanistic studies on palmitate exposed hepatic cells demonstrated that NAFLD-like oxidative damage and lipid accumulation could be reversed by FGF1△HBS . In palmitate-treated hepatic cells, small interfering RNA (siRNA) knockdown of Nrf2 abolished only FGF1△HBS antioxidative actions but not improvement of lipid metabolism. In contrast, AMPK inhibition by pharmacological agent or siRNA abolished FGF1△HBS benefits on both oxidative stress and lipid metabolism that were FGF receptor (FGFR) 4 dependent. Further support of these in vitro findings is that liver-specific AMPK knockout abolished therapeutic effects of FGF1△HBS against high-fat/high-sucrose diet-induced hepatic steatosis. Moreover, FGF1△HBS improved high-fat/high-cholesterol diet-induced steatohepatitis and fibrosis in apolipoprotein E knockout mice. CONCLUSIONS: These findings indicate that FGF1△HBS is effective for preventing and reversing liver steatosis and steatohepatitis and acts by activation of AMPK through hepatocyte FGFR4.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Lin Q, Huang Z, Cai G, et al. Activating Adenosine Monophosphate-Activated Protein Kinase Mediates Fibroblast Growth Factor 1 Protection From Nonalcoholic Fatty Liver Disease in Mice. Hepatology. 2021. PMID: 32965675. doi:10.1002/hep.31568

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。